首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

醫藥CDMO市場規模、佔有率和成長分析：按服務、分子類型、產品類型、劑型、最終用戶、治療領域和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2048907

醫藥CDMO市場規模、佔有率和成長分析：按服務、分子類型、產品類型、劑型、最終用戶、治療領域和地區分類－2026-2033年產業預測

Pharmaceutical CDMO Market Size, Share, and Growth Analysis, By Service, By Molecule Type, By Product Type, By Dosage Form, By End User, By Therapeutic Area, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月21日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球醫藥 CDMO 市值為 2,350 億美元，預計到 2033 年將從 2025 年的 2,526.3 億美元成長至 4,505.5 億美元，在預測期（2026-2033 年）內複合年成長率為 7.5%。

全球醫藥合約研發生產力機構（CDMO）市場的主要驅動力是市場對外包服務日益成長的需求，這些服務旨在最大限度地縮短產品上市時間和減少資本投入，同時提供專業的技術專長。合約研發生產機構為原料藥和學名藥藥公司提供涵蓋原料藥（API）和成品藥的全面服務。外包對這些公司至關重要，使它們能夠專注於藥物研發，同時利用專業合作夥伴的生產能力。此外，複雜生物製藥的不斷發展和日益嚴格的監管標準正促使許多公司放棄自建生產設施。這一趨勢凸顯了CDMO的戰略價值，它們提供的柔軟性和效率，從而推動了醫藥製造業的成長。

全球醫藥CDMO市場成長要素

隨著製藥公司越來越依賴合約研發生產機構（CDMO）在生物製藥領域的專業知識，全球製藥CDMO市場正經歷顯著成長。生物製藥生產的複雜性帶來了巨大的財務和技術挑戰，促使企業將這些流程外包。此外，許多公司旨在最佳化內部資源，專注於核心職能，同時將日益多樣化和複雜的生物製藥候選藥物的研發和生產等複雜任務委託給CDMO。這一趨勢反映了一種策略轉變，即利用CDMO的能力來更有效率、更有效地滿足特定專案的需求。

全球醫藥CDMO市場的限制因素

全球醫藥合約研發生產力機構 (CDMO) 市場面臨嚴峻挑戰，各地監管要求不盡相同，給這些機構帶來了沉重的合規負擔。製程驗證、品質系統和文件編制的日益複雜化，阻礙了它們建構符合各法規結構的合規流程。隨著 CDMO 努力滿足各種監管要求，對專業知識和嚴格控制流程的需求日益成長，尤其是對於中小規模的供應商而言，這推高了它們的營運成本。這種情況可能會阻礙它們建立必要的基礎設施，延長新計畫的推出，並使與多個監管機構的協調變得更加複雜。

全球醫藥CDMO市場趨勢

全球醫藥CDMO市場正日益受到複雜生物製藥和個人化醫療需求成長的影響，促使製藥公司與擁有專業知識的CDMO建立更深入的夥伴關係。這一趨勢凸顯了先進細胞和基因療法、高活性生物製藥處理以及製劑創新方面的能力需求。透過外包這些專業流程，企業可以有效率地加快研發進度，同時降低技術風險。這種合作模式能夠利用擴充性的生物製程平台，並促進知識轉移。這不僅能夠幫助企業獲得專業人才，還能促進創新。因此，企業無需投入大量內部資金即可提高市場應對力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Lonza
Catalent
Thermo Fisher Scientific
WuXi AppTec
Samsung Biologics
Recipharm
Cambrex
Jubilant Pharmova
Piramal Pharma
Boehringer Ingelheim
Siegfried Holding
Fujifilm
Almac Group
Vetter Pharma
CordenPharma
Patheon
AGC Biologics
PCI Pharma Services
Laurus Labs
AbbVie

結論與建議

簡介目錄

Product Code: SQMIG35I2635

Global Pharmaceutical Cdmo Market size was valued at USD 235.0 Billion in 2024 and is poised to grow from USD 252.63 Billion in 2025 to USD 450.55 Billion by 2033, growing at a CAGR of 7.5% during the forecast period (2026-2033).

The global pharmaceutical CDMO market is primarily propelled by the rising demand for externalized capabilities that minimize time to market and capital investment while delivering specialized technical expertise. Contract development and manufacturing organizations offer comprehensive services for both drug substance and drug product functions for innovator and generic companies. Outsourcing is pivotal for these firms, enabling them to focus on drug discovery while leveraging the production capabilities of specialized partners. Additionally, the evolution of complex biologics and heightened regulatory standards has led many companies to shift from operating their own manufacturing facilities. This trend underscores the strategic value of CDMOs in providing flexibility and efficiency, thus driving growth within the pharmaceutical manufacturing landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Cdmo Market Segments Analysis

Global pharmaceutical cdmo market is segmented by service, molecule type, product type, dosage form, end user, therapeutic area and region. Based on service, the market is segmented into Drug Development Services and Manufacturing Services. Based on molecule type, the market is segmented into Small Molecules and Large Molecules. Based on product type, the market is segmented into Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF). Based on dosage form, the market is segmented into Oral Solid Dosage, Injectable, Topical, Inhalation, Nasal and Ophthalmic. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Generic Drug Companies, Emerging Biopharma Companies and Others. Based on therapeutic area, the market is segmented into Oncology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Diseases, Metabolic Disorders and Immunology. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceutical Cdmo Market

The Global Pharmaceutical CDMO market is experiencing significant growth as pharmaceutical companies turn to contract development and manufacturing organizations for their specialized expertise in biologics. The complexities associated with biologic product manufacturing create substantial financial and technical challenges, prompting organizations to outsource these processes. Additionally, many companies aim to optimize their internal resources by focusing on core functions while relying on CDMOs to handle the intricacies of developing and manufacturing an expanding range of diverse and complex biologic candidates. This trend reflects a strategic shift towards leveraging CDMO capabilities to address specific project needs more efficiently and effectively.

Restraints in the Global Pharmaceutical Cdmo Market

The global pharmaceutical Contract Development and Manufacturing Organization (CDMO) market faces significant challenges due to the diverse regulatory expectations that vary across regions, placing a heavy compliance burden on these organizations. The increasing complexity surrounding process validation, quality systems, and documentation complicates their ability to create compliant processes tailored to each regulatory framework they encounter. As CDMOs strive to navigate varying regulatory requirements, the necessity for specialized expertise and meticulously controlled procedures raises operational costs, particularly for small and medium-sized providers. This situation hampers their capacity to develop the necessary infrastructure and may prolong the onboarding of new projects, complicating their alignment with multiple regulatory bodies.

Market Trends of the Global Pharmaceutical Cdmo Market

The Global Pharmaceutical CDMO market is increasingly shaped by the burgeoning demand for complex biologics and personalized medicines, prompting pharmaceutical companies to forge deeper partnerships with CDMOs that possess specialized expertise. This trend emphasizes the need for capabilities in advanced cell and gene therapies, high-potency biologic handling, and formulation innovation. By outsourcing these specialized processes, companies can efficiently accelerate their development timelines while mitigating technical risks. This collaboration enables the utilization of scalable bioprocessing platforms and facilitates knowledge transfer, allowing access to niche talent while fostering innovation. As a result, firms can enhance their market responsiveness without the need for substantial in-house capital investment.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Pharmaceutical CDMO Market Size by Service & CAGR (2026-2033)

Market Overview
Drug Development Services
Manufacturing Services

Global Pharmaceutical CDMO Market Size by Molecule Type & CAGR (2026-2033)

Market Overview
Small Molecules
Large Molecules
- Monoclonal Antibodies
- Biosimilars
- Cell & Gene Therapies
- Antibody-Drug Conjugates
- Vaccines

Global Pharmaceutical CDMO Market Size by Product Type & CAGR (2026-2033)

Market Overview
Active Pharmaceutical Ingredients (API)
Finished Dosage Forms (FDF)

Global Pharmaceutical CDMO Market Size by Dosage Form & CAGR (2026-2033)

Market Overview
Oral Solid Dosage
Injectable
Topical
Inhalation
Nasal
Ophthalmic

Global Pharmaceutical CDMO Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical Companies
Biotechnology Companies
Generic Drug Companies
Emerging Biopharma Companies
Others

Global Pharmaceutical CDMO Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
Cardiovascular Diseases
Infectious Diseases
Neurology
Respiratory Diseases
Metabolic Disorders
Immunology

Global Pharmaceutical CDMO Market Size & CAGR (2026-2033)

North America (Service, Molecule Type, Product Type, Dosage Form, End User, Therapeutic Area)
- US
- Canada
Europe (Service, Molecule Type, Product Type, Dosage Form, End User, Therapeutic Area)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, Molecule Type, Product Type, Dosage Form, End User, Therapeutic Area)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, Molecule Type, Product Type, Dosage Form, End User, Therapeutic Area)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Service, Molecule Type, Product Type, Dosage Form, End User, Therapeutic Area)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cambrex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharmova
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetter Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CordenPharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patheon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PCI Pharma Services
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laurus Labs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments